Targeted Oncology - Immunotherapy, Biomarkers, and Cancer …
In an interview with Peers & Perspectives in Oncology, Doris M. Ponce, MD, MS, a bone marrow transplant specialist, discussed how telehealth made a significant impact on patients with rare diseases receiving medical care and why the rules from the COVID-19 era should be brought back to continue helping these patients.
Perioperative Pembrolizumab Betters Survival in Stage III/IV Head …
Oct 8, 2024 · Perioperative pembrolizumab (Keytruda) led to improved event-free survival (EFS) in patients with stage III or IVA, resected head and neck squamous cell carcinoma (HNSCC), meeting the primary end point of the phase 3 KEYNOTE-689 study (NCT03765918). 1 “These results are substantial, as KEYNOTE-689 marks the first positive trial in 2 decades for patients with resected, locally advanced head ...
Challenges Facing Cancer Survivors - targetedonc.com
Oct 10, 2024 · Cancer survivors often face a unique set of challenges that can impact their physical, emotional, and social well-being. Some of the most common challenges include physical like fatigue or pain, emotional, social, and financial.
Lenalidomide Break Possible? Study Shows Hope for MRD …
Oct 7, 2024 · Minimal residual disease (MRD) negativity was maintained for at least 1 year after stopping lenalidomide (Revlimid) maintenance in patients with multiple myeloma, according to findings from an observational trial (NCT04221178) presented at the 21st International Myeloma Society Annual Meeting. 1. Findings showed that among evaluable patients (n = 39), the MRD-negativity rate at 12 months ...
Adjuvant T-DM1 Continues to Outperform Trastuzumab in HER2 …
Dec 8, 2023 · After 8.4 years follow-up, T-DM1 (ado-trastuzumab emtansine; Kadcycla) led to improved overall survival (OS) and invasive disease-free survival (iDFS) over trastuzumab (Herceptin) in patients with HER2-positive early breast cancer that had residual invasive disease after neoadjuvant therapy, according to findings from the KATHERINE trial that were presented at the 2023 San Antonio Breast ...
Positive Trials Continue to Shape the SCLC Treatment Landscape
Nov 8, 2024 · Recent advancements in small cell lung cancer (SCLC) treatments have introduced transformative therapies and trial results, according to Ariel Lopez-Chavez MD.
Upcoming Endocrine Therapy Developments Excite in Breast Cancer
Oct 25, 2024 · In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Ivonescimab Reduces Risk of Progression Over Pembrolizumab in …
Oct 24, 2024 · Ivonescimab reduced the risk of disease progression or death by 49% compared with pembrolizumab (Keytruda) in patients with PD-L1–positive advanced non–small cell lung cancer (NSCLC).
Antibody-Drug Conjugates Show Unique Advantage in Breast …
Nov 19, 2024 · Erika P. Hamilton, MD, director of breast cancer and gynecologic cancer research at the Sarah Cannon Research Institute, discusses antibody-drug conjugates (ADCs) in multiple types of breast cancer, and when to use these drugs in sequence.
Dato-DXd Shows Promising Efficacy in Endometrial and Ovarian …
Sep 15, 2024 · The TROP2-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) showed promising antitumor activity with manageable toxicity in patients with advanced/metastatic ovarian and endometrial cancer and progressive disease following platinum chemotherapy, according to results from the phase 2 TROPION-PanTumor03 (NCT05489211) study presented at the 2024 ESMO Congress. 1